Eurofins Scientific share among the sharpest declines on the CAC 40 after +22% over the quarter
After a series of records posted since mid-September, Eurofins Scientific paused on Wednesday, losing ground in a CAC 40 itself slightly in the red. Today's pullback occurs as the stock maintains a particularly solid quarterly momentum.
A moderate pullback that leaves intact a comfortable gap above moving averages
Eurofins Scientific lost 1.85% during the session, at 77.50 €, after reaching a peak of 77.88 € in the previous session. The stock has retreated from its short-term resistance at 78.96 €, which it was still testing the previous day, without any critical support being threatened. With a gain of nearly 22% over the quarter and more than 5% over the week, today's bearish movement remains very contained relative to recent momentum. The stock ranks among the sharpest declines on the CAC 40 during the session, in an index that itself declined 0.32%.
The three moving averages remain well below the current price: the 20-day MA at 73.38 €, a gap of 5.6% below the current price, and the 200-day MA at 66.27 €, nearly 17% under the price. This technical cushion provides room before consolidation takes on a more concerning turn. The RSI at 76, on the other hand, signals an overbought configuration, consistent with the amplitude of the recent rebound and arguing for a breathing phase after several weeks of gains.
A second half 2026 that confirms improvement, with an American acquisition in sight for the fourth quarter
When publishing first-half 2026 results on July 23, 2026, management had displayed a confident tone on the profitability trajectory, indicating that profitability was approaching the 2027 target more than a year ahead of schedule and that the decline in investment levels was beginning to translate into significantly higher cash generation. Organic revenue growth, still below a normalized pace at the beginning of the fiscal year, had improved throughout the semester, even though BioPharma auxiliary activities in North America remained under pressure. A notable acquisition also featured in the outlook: the acquisition of Element Materials Technology in North America, which would add life sciences testing services for more than $150 million in annual revenue, was expected for the fourth quarter of 2026.
This fundamental context supports the stock revaluation since the beginning of September, even though today's pullback illustrates the natural consolidation trend after such rapid progression. The share buyback program, which totaled 483 million euros over twelve months according to the latest declaration of September 11, 2026, constitutes structural support for the capital. The support at 69.60 € remains the key reference in case of more pronounced correction.
